Regardless of the actual cancer risk inherent in a particular mutation, an increasingly common clinical recommendation for BRCA1/2 gene mutation carriers is PSO, as it has been shown by several groups to lower risk of ovarian, fallopian tube, and epithelial cancer by 80%, and reduce mortality risk by 77% [37, 43–45]. Here, BRCA1 is linked to cancer.